Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
dc.contributor.author | Aguillon, David | |
dc.contributor.author | Langella, Stephanie | |
dc.contributor.author | Chen, Yinghua | |
dc.contributor.author | Sanchez, Justin | |
dc.contributor.author | Su, Yi | |
dc.contributor.author | Vila-Castelar, Clara | |
dc.contributor.author | Vasquez, Daniel | |
dc.contributor.author | Zetterberg, Henrik | |
dc.contributor.author | Hansson, Oskar | |
dc.contributor.author | Dage, Jeffrey L. | |
dc.contributor.author | Janelidze, Shorena | |
dc.contributor.author | Chen, Kewei | |
dc.contributor.author | Fox-Fuller, Joshua T. | |
dc.contributor.author | Aduen, Paula | |
dc.contributor.author | Martinez, Jairo E. | |
dc.contributor.author | Garcia, Gloria | |
dc.contributor.author | Baena, Ana | |
dc.contributor.author | Guzman, Claudia | |
dc.contributor.author | Johnson, Keith | |
dc.contributor.author | Sperling, Reisa A. | |
dc.contributor.author | Blennow, Kaj | |
dc.contributor.author | Reiman, Eric M. | |
dc.contributor.author | Lopera, Francisco | |
dc.contributor.author | Quiroz, Yakeel T. | |
dc.contributor.department | Neurology, School of Medicine | |
dc.date.accessioned | 2024-09-09T12:24:15Z | |
dc.date.available | 2024-09-09T12:24:15Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Introduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members. Results: Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels and cognitive function. Discussion: Our findings suggest that plasma p-tau217 predicts subsequent brain pathological burden and memory performance in presenilin-1 E280A carriers. These results provide support for plasma p-tau217 as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials. Highlights: Non-demented presenilin-1 E280A carriers have higher plasma tau phosphorylated at threonine 217 (p-tau217) than do age-matched non-carriers. Higher baseline p-tau217 is associated with greater future amyloid positron emission tomography (PET) pathology burden. Higher baseline p-tau217 is associated with greater future tau PET pathology burden. Higher baseline p-tau217 is associated with worse future memory performance. | |
dc.eprint.version | Author's manuscript | |
dc.identifier.citation | Aguillon D, Langella S, Chen Y, et al. Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2023;19(6):2585-2594. doi:10.1002/alz.12906 | |
dc.identifier.uri | https://hdl.handle.net/1805/43205 | |
dc.language.iso | en_US | |
dc.publisher | Wiley | |
dc.relation.isversionof | 10.1002/alz.12906 | |
dc.relation.journal | Alzheimer's & Dementia | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Autosomal dominant Alzheimer's disease | |
dc.subject | Blood biomarkers | |
dc.subject | Dementia | |
dc.subject | Presenilin-1 | |
dc.subject | Tau pathology | |
dc.title | Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease | |
dc.type | Article |